XML 34 R19.htm IDEA: XBRL DOCUMENT
v3.22.0.1

REVENUES | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
REVENUES |
REVENUES
Contract Balances The timing of revenue recognition, billings and cash collections results in the recognition of trade accounts receivable, unbilled receivables, contract assets, and customer advances and deposits (contract liabilities) on our consolidated balance sheets. Net trade accounts receivable was $2.4 billion and $1.7 billion as of December 31, 2021 and 2020, respectively. For contract manufacturing arrangements, revenue is primarily recognized throughout the production cycle, which typically lasts up to 90 days, resulting in the recognition of contract assets until the related services are completed and the customers are billed. Additionally, for arrangements containing a performance obligation to deliver software that can be used with medical devices, we recognize revenue upon delivery of the software, which results in the recognition of contract assets when customers are billed over time, generally over one to five years. For bundled contracts involving equipment delivered up-front and consumable medical products to be delivered over time, total contract revenue is allocated between the equipment and consumable medical products. In certain of those arrangements, a contract asset is created for the difference between the amount of equipment revenue recognized upon delivery and the amount of consideration initially receivable from the customer. In those arrangements, the contract asset becomes a trade account receivable as consumable medical products are provided and billed, generally over one to seven years. The following table summarizes our contract assets:
as of December 31 (in millions) | 2021 | 2020
Contract manufacturing services | $ | 50 |  | $ | 47 |
Software sales | 45 |  | 40 |
Bundled equipment and consumable medical products contracts | 100 |  | 47 |
Contract assets | $ | 195 |  | $ | 134 |
The following table summarizes the classification of contract assets and contract liabilities as reported in the consolidated balance sheet:
as of December 31 (in millions) | 2021 | 2020
Prepaid expenses and other current assets | $ | 84 |  | $ | 70 |
Other non-current assets | 111 |  | 64 |
Contract assets | $ | 195 |  | $ | 134 |
Accrued expenses and other current liabilities | $ | 162 |  | $ | 32 |
Other non-current liabilities | 84 |  | 34 |
Contract liabilities | $ | 246 |  | $ | 66 |
In 2021, $20 million of revenue was recognized that was included in contract liabilities as of December 31, 2020. In 2020 and 2019, the amount of revenue recognized that was included in contract liabilities as of December 31, 2019 and 2018 was not significant. Disaggregation of Net Sales Beginning in the first quarter of 2021, our product category net sales disclosures (previously referred to as global business units (GBUs)) separately present net sales from our BioPharma Solutions business, which was previously included within Other. Concurrent with that disaggregation of net sales from our BioPharma Solutions business, we have also allocated certain previously unallocated sales deductions from Other to various categories, primarily based on their respective net sales. Net sales for 2020 and 2019 have been recast to conform to this presentation. Additionally, with the acquisition of Hillrom in December 2021, we have added three new product categories: Patient Support Systems, Front Line Care and Surgical Solutions. The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
| 2021 |  | 2020 |  | 2019
years ended December 31 (in millions) | U.S. | International | Total |  | U.S. | International | Total |  | U.S. | International | Total
Renal Care 1 | $ | 890 |  | $ | 3,010 |  | $ | 3,900 |  |  | $ | 848 |  | $ | 2,909 |  | $ | 3,757 |  |  | $ | 791 |  | $ | 2,848 |  | $ | 3,639 |
Medication Delivery 2 | 1,859 |  | 1,021 |  | 2,880 |  |  | 1,738 |  | 953 |  | 2,691 |  |  | 1,762 |  | 977 |  | 2,739 |
Pharmaceuticals 3 | 753 |  | 1,538 |  | 2,291 |  |  | 849 |  | 1,249 |  | 2,098 |  |  | 904 |  | 1,215 |  | 2,119 |
Clinical Nutrition 4 | 343 |  | 621 |  | 964 |  |  | 330 |  | 580 |  | 910 |  |  | 308 |  | 552 |  | 860 |
Advanced Surgery 5 | 545 |  | 432 |  | 977 |  |  | 516 |  | 370 |  | 886 |  |  | 533 |  | 342 |  | 875 |
Acute Therapies 6 | 287 |  | 495 |  | 782 |  |  | 286 |  | 454 |  | 740 |  |  | 184 |  | 351 |  | 535 |
BioPharma Solutions 7 | 273 |  | 396 |  | 669 |  |  | 234 |  | 252 |  | 486 |  |  | 257 |  | 212 |  | 469 |
Patient Support Systems 8 | 86 |  | 29 |  | 115 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Front Line Care 9 | 51 |  | 19 |  | 70 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Surgical Solutions 10 | 12 |  | 15 |  | 27 |  |  | — |  | — |  | — |  |  | — |  | — |  | — |
Other 11 | 81 |  | 28 |  | 109 |  |  | 77 |  | 28 |  | 105 |  |  | 87 |  | 39 |  | 126 |
Total Baxter | $ | 5,180 |  | $ | 7,604 |  | $ | 12,784 |  |  | $ | 4,878 |  | $ | 6,795 |  | $ | 11,673 |  |  | $ | 4,826 |  | $ | 6,536 |  | $ | 11,362 |
1 Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. 2 Medication Delivery includes sales of our IV therapies, infusion pumps, administration sets and drug reconstitution devices. 3 Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. 4 Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products. 5 Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. 6 Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU). 7 BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies. 8 Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies. 9 Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment. 10 Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. 11 Other includes sales of miscellaneous product and service offerings.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration